Mental health insurance problems continue: 5 things to check before buying a cover
Getty Images All general and standalone health insurers do abide by the Mental Healthcare Act, 2017, and include mental illnesses in their health plans
There has been a 30-50% rise in mental health-related claims in the past 2-3 years, claims a recent study by Policybazaar (see graphic). 'We've also seen a 41% year-on-year growth in mental health insurance searches in 2025,' says Siddharth Singhal, Head of Health Insurance, Policybazaar.
The surge is corroborated by Bhaskar Nerurkar, Head, Health Administration Team, Bajaj Allianz General Insurance: 'We've seen a steady increase in mental health related claims, with a CAGR of about 33% from 2021-22 to 2024-25. In the last year alone, there was a 23% rise in such claims over the previous year.'
These figures seem reassuring in the face of grim societal stigma and the fact that 10.6% of adults in India suffer from mental disorders and the lifetime prevalence of mental disorders is 13.7%, as per the National Mental Health Survey 2015-16 by NIMHANS.However, Anuradha Sriram, Chief Actuarial Officer, Aditya Birla Health Insurance, strikes a discordant note. 'While awareness and conversation around mental health have increased in recent years, we have not observed a significant rise in mental health related hospitalisation claims,' she says. This is because most treatments for mental health continue to be outpatient-based, which are generally not captured in the scope of hospitalisation plans, she explains.
The in-patient focus of most plans is only one of the several problems faced by people seeking mental health covers despite the insurance regulator's proactive approach in widening the scope of coverage.
Though the Mental Healthcare Act, 2017, was enforced in May 2018, Irdai was forced to issue circulars in August 2018 and then again in October 2022, requesting compliance by insurers and removal of mental illnesses from their list of exclusions. The guidelines stated that mental illnesses had to be treated at par with physical illnesses when it came to providing coverage.While insurers eventually started offering mental health coverage in their plans by the end of 2022, in February 2023, Irdai was again forced to issue a circular to 'mandatorily launch and immediately offer' an 'appropriate product' and a 'specific cover' for persons with mental illnesses, disabilities and HIV/AIDS, which translated to a standardised, standalone cover.A crucial inclusion was the need to put in place a 'Board-approved underwriting policy that ensures no proposal is denied'. This meant the insurers could not refuse a cover to a person with pre-existing mental disorders.Today, all general and standalone health insurers do abide by the Mental Healthcare Act, 2017, and include mental illnesses in their health plans. 'We offer mental health coverage as part of our health insurance plans in alignment with Irdai guidelines. The plans typically cover hospitalisation expenses arising from mental illnesses, including depression, anxiety, bipolar disorder and schizophrenia,' says Priya Deshmukh, Head, Health Product, Operations & Services, ICICI Lombard. Other insurers too cover mental illnesses under their comprehensive plans.In-patient, not OPD plans: The problem with most such covers is that these are indemnity plans that only cover hospitalisation or in-patient expenses, whereas most mental disorders require periodic doctor consultations, therapies, counselling, medication and psychiatric evaluations, which are out-patient features. Policybazaar data shows that conditions like anxiety (30-35%) and depression (25-30%) are the top reasons for claims, which are usually managed through out-patient care rather than inpatient admission. Without these features and benefits, the insurance policy may not be of much use to you.
1. Does it have a pre-existing disease waiting period? If the applicant already suffers from a mental illness, buying a plan may be a challenge, depending on the severity of the disorder. In all probability, he will have to clear the waiting period for pre-existing diseases, which is 2-3 years for most insurers, before he can be covered for the disorder.
2. Does it offer OPD benefit? Doctor consultations and medication are an integral part of mental health treatments, which can only be covered by a plan with an OPD feature. So, if OPD benefit is missing, either as a part of the base cover or as an optional feature, the plan won't be of much use to you.
3. Does it cover therapy & counselling? Even if the OPD benefit is included in the plan, not all insurers offer all the features that are crucial for mental health treatments, such as therapy, counselling and psychiatric evaluations, which can be very expensive. Make sure these are a part of the cover.
4. Is your therapist or health care centre in the network? Most insurers require the treatment to be conducted by a qualified practitioner in a recognised institute, hospital or clinic that falls in its network. If these don't fulfill the insurer requirements, you will not be able to make a claim.
5. Is your illness covered?
You will need to ensure that your particular mental illness is included in the plan. The disorders usually covered by insurers include anxiety, depression, bipolar disorder, schizophrenia, PTSD and dementia. If the illness is not covered, there's no point buying the cover. Agrees Sriram: 'Our flagship products are hospitalisation-focused indemnity plans, covering in-patient treatment for mental health conditions. However, many mental health treatments, like therapy or consultations, are outpatient in nature and are not covered under the base plan.''OPD coverage is crucial even as an addon because a plan that only covers hospitalisation may not suffice for real-world needs,' says Singhal. So, either the policy buyer needs to find a plan that has an in-built OPD feature, or buy an OPD rider along with the base cover, both of which require additional expense due to higher premiums that these entail.
Underwriting hurdles: For people with existing mental conditions, especially with a high degree of severity, it can be difficult to buy a plan despite Irdai specifying that insurers cannot refuse it. 'While Irdai has mandated insurers to cover mental health conditions, underwriting still applies. This means that individuals with a known history of mental illness may face medical assessments, loading on premiums, or specific exclusions,' says Deshmukh. This could mean either expensive plans, limits on coverage, or long waiting periods, usually between two and three years, and sometimes even rejection for severe disorders.
Network practitioners: Since the treatment for many mental illnesses requires therapy and counselling, many people pick private therapists or clinics, which may not be in the insurer networks or empanelled. Besides, correct diagnosis and effective therapy can often mean sifting through various doctors and counsellors before finding the right one that suits the patient, and not every such practitioner may be a part of the insurer network.
Standardised plans: Many general and standalone health insurance companies offer a standardised plan that provides a cover of `4-5 lakh and includes mental illnesses among other disabilities and disorders. This standardised plan is an affordable base plan with similar offerings across insurers, but is available under different names and varying premiums, which is typically low. However, since it is not a comprehensive plan and offers low coverage, it means the policyholders would need to pad it up, besides buying another cover for other illnesses as well. 'Consumers should look for comprehensive plans that include mental health as part of their base coverage and evaluate whether the insurer offers any additional riders/add-ons that support out-patient care or wellness programs,' says Sriram.Agrees Nerurkar. 'It's advisable to consider whether the policy offers OPD benefits for consultations, therapy sessions, and medication. Some plans also provide wellness programs or teleconsultation services, which can be highly valuable for ongoing support. Transparency regarding waiting periods, exclusions (like illnesses related to substance abuse), and pre-existing condition disclosures is critical to ensuring seamless claims later,' he says.One should also check whether the insurer has a strong hospital network with the required facilities. 'Ensure that the insurer's network hospitals include facilities offering psychiatric services and that these are accessible in your area,' says Deshmukh.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
NDTV
4 hours ago
- NDTV
Can Anti-Ageing Drugs Cause Cardiac Arrest? Doctors Explain Shefali Jariwala Death
On June 27, 2025, when news of the tragic and sudden death of actress Shefali Jariwala broke, it left everyone in shock. The 42-year-old actress, who rose to fame with the iconic remix of the Kaanta Laga song that every Y2K person knows about, died suddenly from a possible cardiac arrest, leading to various speculation about the cause of her death. One such cause, according to sources, points to the use of so-called age-defying anti-ageing treatments, which might come with hidden, and sometimes fatal, cardiovascular risks. The Toxic Cocktail Of Anti-Ageing Treatments And Fasting Reports suggest that Shefali, who had a history of epilepsy, might have received a cosmetic anti-ageing injection containing Glutathione and Vitamin C on empty stomach, which was potentially followed by a sudden drop in blood pressure leading to cardiac arrest. While the exact cause of death is under investigation, and a post-mortem report is awaited, medical experts across India are cautioning against the use of unregulated anti-ageing therapies. Dr Anesh Jain, Consultant Cardiologist at Ruby Hall Clinic, Pune, explains to NDTV, "Although glutathione and Vitamin C are widely used in skin treatments, introducing such compounds in a dehydrated or fasted state can place unnecessary stress on the cardiovascular system. In rare cases, this can result in a dangerous drop in blood pressure, possibly leading to cardiac arrest." He adds, "There is no formal category of 'anti-ageing' drugs approved by the FDA (US Food and Drug Administration). Most of these treatments are off-label, experimental, or cosmetic in nature - and lack proper long-term cardiovascular safety data." A quick research showed that the FDA has explicitly warned against the use of glutathione powder intended for dietary supplements to compound sterile injectable drugs due to safety concerns, including reports of adverse events linked to endotoxin contamination in compounded glutathione injections. Moreover, injectable glutathione is also not FDA-approved for skin lightening. In fact, there are no published clinical trials or official guidelines supporting the safety or efficacy of injectable glutathione for skin whitening. Rather, the FDA has highlighted risks such as toxic effects on the liver, kidneys, and nervous system, and potential severe reactions like Stevens-Johnson Syndrome. Injectable Vitamin C products are also not FDA-approved for skin lightening. In 2019, the FDA requested all companies to stop distributing unapproved versions of ascorbic acid (Vitamin C) injection. In India, the Central Drugs Standard Control Organisation (CDSCO) have approved glutathione and Vitamin C injections but only for specific medical indications, not for cosmetic or skin whitening purposes. The Problem With Anti-Ageing Treatments Experts suggest that while glutathione and Vitamin C are not known to directly affect the heart, their impact when used without proper medical context - such as being taken intravenously on an empty stomach or alongside other drugs - can trigger a dangerous cascade, potentially including hypotension and cardiac arrest. And this is not just about glutathione or Vitamin C. It's about a range of anti-ageing drugs. Dr Srinivas Kudva, Interventional Cardiologist at Lilavati Hospital, explains that anti-ageing drugs have gained immense popularity in recent years, driven by a global interest in longevity and the prevention of age-related decline. "These therapies target various biological mechanisms, ranging from hormone modulation (eg, testosterone, growth hormone) to cellular metabolism and mitochondrial function (eg, NAD+ boosters, mTOR inhibitors). While many are designed to enhance cellular resilience and slow biological ageing, their effects on cardiovascular health are not uniformly positive and remain under active investigation," he adds. He explains that these hormonal agents can significantly influence cardiovascular dynamics. "Elevated testosterone or growth hormone levels may increase red blood cell production, elevate blood pressure, and alter lipid metabolism, all of which can contribute to a higher risk of arrhythmias, arterial stiffness, or thrombotic events. Even newer compounds like NAD+ precursors, though marketed for their regenerative properties, may accelerate metabolic activity and place excess strain on the heart, especially in individuals with pre-existing cardiovascular vulnerabilities," Dr Kudva says. Women's Hearts At Greater Risk Both globally and in India, cardiovascular disease (CVD) is now the leading cause of death in women - surpassing even breast cancer. Dr Ashish Agarwal, Director Of Cardiology At Aakash Healthcare, points out, "CVDs are often overlooked in women. In fact, heart attacks and cardiac arrests kill 10 times more women than breast cancer. One in five Indian women aged 15-49 has untreated hypertension. Early screening is crucial." Adding to this, Dr Subrat Akhoury, Chairman of the Cath Lab and Head of Unit-I at Asian Hospital, says, "Women's heart attack symptoms are frequently misdiagnosed. Nausea, fatigue, shortness of breath - these can be mistaken for other issues. Plaque builds up differently in women's arteries, making diagnosis tricky. Emotional stress and depression - which are more common in women - can also raise cardiac risk." He added a stark warning, "It's crucial that patients understand the heart is especially vulnerable to untested hormone-altering anti-ageing drugs. Cardiac arrest can be the first and final symptom." Low Blood Pressure: A Silent Trigger One of the potential complications in Shefali's case could have been a sudden drop in blood pressure - a known trigger for cardiac arrest. Dr Abhijit Khadtare, Cardiologist At Ruby Hall Clinic, Pune, explains, "Severe hypotension, or a sudden and steep drop in blood pressure, is a medical emergency. It can deprive vital organs of oxygen, leading to shock - a life-threatening condition." He elaborated that causes of sudden hypotension include: Severe dehydration or blood loss Septic shock from infections Anaphylactic reactions Heart attack or failure "Symptoms like confusion, fainting, rapid weak pulse and cold, sweaty skin should never be ignored. Immediate medical attention is vital to prevent fatal outcomes," Dr Khadtare says. The Need For Supervision According to police sources, Shefali had been taking heavy doses of anti-ageing, multivitamin, and skin whitening medications for many years without any doctor's supervision, indicating this could be a case of self-medication. The Amboli police found a large number of medicines in Shefali's room - in the fridge, drawer, and on the table - including anti-ageing medication like glutathione. Shefali started taking medicines on her own about eight years ago after consulting a doctor once, and continued this without regular monitoring by any current doctor, said sources. Dr Praveen Gupta, Chairman of Marengo Asia International Institute of Neuro and Spine and Chief Clinical Strategy for the North India region, warned against the growing trend of self-medication with anti-ageing treatments. "People assume 'natural' or 'anti-ageing' means safe. That's simply not true. Many of these drugs interact with existing medications for blood pressure or diabetes. In older adults, this can be especially dangerous," he says. He stressed that these substances are often sold online, bypassing regulations and quality checks. "We need to treat anti-ageing interventions like any other medical procedure - only under professional guidance. Without proper screening, these so-called youth elixirs can pose serious risks," Dr Gupta concludes. Actress-model Shefali Jariwala's death puts the spotlight back on the rise of self-medication and anti-ageing treatments, with devastating consequences.
Hans India
4 hours ago
- Hans India
IISc Bangalore researchers develop simple, cost-effective sensor for detecting liver cancer
Researchers at the Indian Institute of Science (IISc) have developed a simple sensor that is cost-effective and can enable faster detection of liver cancer. The team focussed on the potential of terbium -- a rare earth metal -- to develop a unique luminescent probe that can sense the presence of an enzyme called beta-glucuronidase. While its core function is to break down a sugar acid called glucuronic acid, the enzyme also doubles as a critical biomarker for liver cancer. An increase in beta-glucuronidase levels has been associated with the risk of colon, breast, and renal cancers, as well as infections of the urinary tract and AIDS. Thus, the novel sensor offers a potentially powerful screening tool against different types of cancers, neonatal jaundice, and NSAID-induced toxicity, said the researchers. 'Conventional methods of colorimetry and fluorescence for detecting such enzymes are often restricted by sensitivity or interference from background signals. The ability of rare earth metals to have long-lived excited states allows us to filter out short-lived background fluorescence, resulting in a much clearer signal,' said Ananya Biswas, former PhD student at IISc and co-first author of the paper published in the journal Chemistry, on Monday. The innovation began with research into the gel-forming properties of metal ions. The IISC team discovered that terbium ions, when incorporated into a gel matrix derived from bile salts, emitted a bright green glow. To this, the researchers added a molecule called 2,3-DHN ((2,3-Dihydroxynaphthalene), masked with glucuronic acid. In the presence of beta-glucuronidase, terbium ions cleave the mask, releasing 2,3-DHN, which then acts as an 'antenna,' absorbing UV light. It also transfers energy to nearby terbium ions, amplifying the green fluorescence, explained Uday Maitra, Professor in the Department of Organic Chemistry, IISc. Further, to make the technology accessible, the team embedded the gel matrix onto paper discs, creating a simple and portable sensor. Exposing the samples containing beta-glucuronidase, these discs emitted a pronounced green glow under UV light. These sensors could also be analysed using a UV lamp and ImageJ -- an open source, freely accessible software, making this technique ideal for resource-limited settings, the team said. The sensor showed a detection limit, which was significantly below the beta-glucuronidase levels typically seen for cirrhosis -- an advanced stage of liver disease. While more clinical studies are needed to validate the findings, such sensors can bring down the cost of detecting clinically significant biomarkers, the researchers said.
Time of India
4 hours ago
- Time of India
IISc team creates glowing sensor for liver cancer detection
BENGALURU: Scientists from the ( ) have developed a simple, glowing paper sensor that could help detect liver cancer early — using the green glow of a rare earth metal called terbium. Tired of too many ads? go ad free now The sensor works by detecting an enzyme called 'β-glucuronidase', which is found in many living organisms. While it has normal biological roles, high levels of this enzyme are linked to liver cancer, as well as colon, breast, and kidney cancers, and even infections and AIDS. 'Traditional detection methods often struggle with background noise or low sensitivity,' said Ananya Biswas, a former PhD student and co-author of the study published in Chemistry. 'But terbium has a unique ability — it glows for longer periods, helping us cut through the noise and get a clearer signal,' she added. IISc said the project began nearly 10 years ago when researchers studied metal ions and their gel-forming abilities. They found that terbium, when embedded in a gel made from bile salts, gives off a bright green glow under ultraviolet (UV) light. 'To create the sensor, the team added a special organic molecule — 2,3-DHN — coated with a sugar acid called glucuronic acid. This coating keeps it 'switched off'. But when β-glucuronidase is present, it cuts away the coating, releasing the active molecule. When UV light is shone on the sample, the molecule absorbs the energy and passes it on to the nearby terbium, boosting its green glow,' IISc said. The researchers embedded this glowing gel onto small paper discs, turning it into an easy-to-use sensor. When exposed to samples with β-glucuronidase, the disc glows brighter under UV light. Tired of too many ads? go ad free now Unlike expensive lab equipment, this sensor can be read using a simple UV lamp and free software called 'ImageJ', making it ideal for low-resource settings, IISc said, adding that the sensor can detect enzyme levels as low as 185 nanograms per millilitre — well below the levels usually seen in serious liver disease. Though further clinical trials are needed, researchers believe the sensor could be a low-cost tool for detecting not just liver cancer, but other conditions linked to the enzyme, including jaundice and drug toxicity.
